Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Seralutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
    Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)

    07 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007084198/en

    BUSINESSWIRE
    07 Oct 2024
    Share Share
    Gossamer To Provide Seralutinib OLE Data At ATS 2024
    Gossamer To Provide Seralutinib OLE Data At ATS 2024

    14 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240514616477/en

    BUSINESSWIRE
    14 May 2024
    Share Share
    Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH
    Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH

    06 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chiesi-and-gossamer-bio-announce-transformative-global-collaboration-to-develop-and-commercialize-seralutinib-in-pulmonary-arterial-hypertension-and-other-respiratory-indications-302136742.html

    PR NEWSWIRE
    06 May 2024
    Share Share
    Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data
    Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data

    13 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231213371661/en

    BUSINESSWIRE
    13 Dec 2023
    Share Share
    Gossamer Announces Seralutinib Meets Endpoint in PII TORREY Study in PAH
    Gossamer Announces Seralutinib Meets Endpoint in PII TORREY Study in PAH

    06 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221206005388/en

    BUSINESSWIRE
    06 Dec 2022
    Share Share
    Gossamer touts phase 2 win but investors are wary
    Gossamer touts phase 2 win but investors are wary

    06 Dec 2022

    // Max Bayer FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/gossamer-touts-phase-2-win-analysts-dont-appear-interested-celebrating

    Max Bayer FIERCEBIOTECH
    06 Dec 2022
    Share Share